Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Measurable Residual Disease Monitoring in AML With FLT3-ITD Treated With Intensive Chemotherapy Plus Midostaurin.

Autor: Rücker FG; University Hospital of Ulm, Ulm, Germany., Bullinger L; Charité University Medicine, Berlin, Germany., Cocciardi S; University Hospital Ulm, Ulm, Germany., Skambraks S; University of Ulm, Ulm, Germany., Luck TJ; University Hospital of Ulm, Germany., Weber D; University Hospital of Ulm, Ulm, Germany., Krzykalla J; German Cancer Research Center, Heidelberg, Germany., Pozek E; German Cancer Research Center, Heidelberg, Germany., Schneider IJ; University Hospital of Ulm, Ulm, Germany., Corbacioglu A; University Hospital of Ulm, Ulm, Germany., Gaidzik VI; University Hospital Ulm, Ulm, Germany., Meid A Dr; University Hospital of Ulm, Ulm, Germany., Aicher S; University Hospital of Ulm, Ulm, Germany., Stegelmann F; University Hospital of Ulm, Ulm, Germany., Schrade A; University Hospital of Ulm, Ulm, Germany., Theis F; University Hospital of Ulm, Ulm, Germany., Fiedler W; Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, Hubertus Wald University Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, Hamburg, Germany., Salih HR; University Hospital, Tuebingen, Germany., Wulf GG; Georg-August University, Goettingen, Germany., Salwender HJ; Asklepios Klinik Altona, Hamburg, Germany., Schroeder T; University of Duesseldorf, Duesseldorf, Germany., Götze KS; Technical University of Munich (TUM) School of Medicine, Munich, Germany., Kühn MWM; University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany., Lübbert M; Medical Center - University of Freiburg, Freiburg, Germany., Schlenk RF; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany, Germany., Benner A; German Cancer Research Center, Heidelberg, Germany., Thol FR; Hannover Medical School, Hannover, Germany., Heuser M; Hannover Medical School, Hannover, Germany., Ganser A; Hannover Medical School, Hannover, Germany., Döhner H; University Hospital Ulm, Ulm, Germany., Döhner K; University Hospital of Ulm, Ulm, Germany.

Publikováno v: Blood advances [Blood Adv] 2024 Sep 30. Date of Electronic Publication: 2024 Sep 30.

AML with complex karyotype: extreme genomic complexity revealed by combined long-read sequencing and Hi-C technology.

Autor: Klever MK; Division of Hematology, Oncology, and Cancer Immunology, Medical Department, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.; RG Development and Disease, Max Planck Institute for Molecular Genetics, Berlin, Germany.; Institute for Medical Genetics and Human Genetics, Charité University Medicine Berlin, Berlin, Germany., Sträng E; Division of Hematology, Oncology, and Cancer Immunology, Medical Department, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany., Hetzel S; Department of Genome Regulation, Max Planck Institute for Molecular Genetics, Berlin, Germany., Jungnitsch J; Institute for Medical Genetics and Human Genetics, Charité University Medicine Berlin, Berlin, Germany.; Human Molecular Genomics Group, Max Planck Institute for Molecular Genetics, Berlin, Germany., Dolnik A; Division of Hematology, Oncology, and Cancer Immunology, Medical Department, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany., Schöpflin R; RG Development and Disease, Max Planck Institute for Molecular Genetics, Berlin, Germany.; Institute for Medical Genetics and Human Genetics, Charité University Medicine Berlin, Berlin, Germany.; Department of Computational Molecular Biology, Max Planck Institute for Molecular Genetics, Berlin, Germany., Schrezenmeier JF; Division of Hematology, Oncology, and Cancer Immunology, Medical Department, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany., Schick F; Division of Hematology, Oncology, and Cancer Immunology, Medical Department, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany., Blau O; Division of Hematology, Oncology, and Cancer Immunology, Medical Department, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.; Labor Berlin - Charité Vivantes GmbH, Berlin, Germany., Westermann J; Division of Hematology, Oncology, and Cancer Immunology, Medical Department, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.; Labor Berlin - Charité Vivantes GmbH, Berlin, Germany., Rücker FG; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Xia Z; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Döhner K; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Schrezenmeier H; Institute of Transfusion Medicine, University of Ulm, Ulm, Germany.; Institute for Clinical Transfusion Medicine and Immunogenetics, German Red Cross Blood Transfusion Service Baden-Württemberg-Hessen and University Hospital Ulm, Ulm, Germany., Spielmann M; Human Molecular Genomics Group, Max Planck Institute for Molecular Genetics, Berlin, Germany.; Institut für Humangenetik Lübeck, Universität zu Lübeck, Lübeck, Germany., Meissner A; Department of Genome Regulation, Max Planck Institute for Molecular Genetics, Berlin, Germany., Melo US; RG Development and Disease, Max Planck Institute for Molecular Genetics, Berlin, Germany.; Institute for Medical Genetics and Human Genetics, Charité University Medicine Berlin, Berlin, Germany., Mundlos S; RG Development and Disease, Max Planck Institute for Molecular Genetics, Berlin, Germany.; Institute for Medical Genetics and Human Genetics, Charité University Medicine Berlin, Berlin, Germany.; Labor Berlin - Charité Vivantes GmbH, Berlin, Germany., Bullinger L; Division of Hematology, Oncology, and Cancer Immunology, Medical Department, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.; Labor Berlin - Charité Vivantes GmbH, Berlin, Germany.; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany.

Publikováno v: Blood advances [Blood Adv] 2023 Nov 14; Vol. 7 (21), pp. 6520-6531.

Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results.

Autor: Rücker FG; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Du L; Novartis Pharmaceuticals, Cambridge, MA, USA., Luck TJ; Department of Hematology, Oncology and Tumor Immunology, Charité University, Berlin, Germany., Benner A; Division of Biostatistics, German Cancer Research Center, Heidelberg, Germany., Krzykalla J; Division of Biostatistics, German Cancer Research Center, Heidelberg, Germany., Gathmann I; Novartis Pharmaceuticals, Basel, Switzerland., Voso MT; Department of Biomedicine and Prevention, Università di Roma 'Tor Vergata', Rome, Italy., Amadori S; Department of Biomedicine and Prevention, Università di Roma 'Tor Vergata', Rome, Italy., Prior TW; The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA., Brandwein JM; Department of Medicine, University of Alberta, Edmonton, AB, Canada., Appelbaum FR; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Medeiros BC; Division of Hematology, Stanford Comprehensive Cancer Center, Stanford University, Stanford, CA, USA., Tallman MS; Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA., Savoie L; University of Calgary, Calgary, AB, Canada., Sierra J; Hematology Department, Hospital de la Santa Creu i Sant Pau and Jose Carreras Leukemia Research Institute, Autonomus University of Barcelona, Barcelona, Spain., Pallaud C; Novartis Pharmaceuticals, Basel, Switzerland., Sanz MA; Hospital Universitario la Fe, Hematology Department, Department of Medicine, University of Valencia, Valencia, Spain., Jansen JH; Radboud Institute Molecular Studies, Radboud University Medical Center, Nijmegen, The Netherlands., Niederwieser D; Hematology and Oncology, University of Leipzig, Leipzig, Germany., Fischer T; Department of Hematology and Oncology, Center of Internal Medicine, Otto-von-Guericke University Magdeburg, Magdeburg, Germany., Ehninger G; Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus der TU Dresden, Dresden, Germany., Heuser M; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Ganser A; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Bullinger L; Department of Hematology, Oncology and Tumor Immunology, Charité University, Berlin, Germany., Larson RA; Department of Medicine and Comprehensive Cancer Center, University of Chicago, Chicago, IL, USA., Bloomfield CD; The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA., Stone RM; Department of Medical Oncology, Dana-Farber/Partners CancerCare, Boston, MA, USA., Döhner H; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Thiede C; Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus der TU Dresden, Dresden, Germany., Döhner K; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany. konstanze.doehner@uniklinik-ulm.de.

Publikováno v: Leukemia [Leukemia] 2022 Jan; Vol. 36 (1), pp. 90-99. Date of Electronic Publication: 2021 Jul 28.

Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial.

Autor: Kapp-Schwoerer S; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Weber D; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Corbacioglu A; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Gaidzik VI; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Paschka P; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Krönke J; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Theis F; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Rücker FG; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Teleanu MV; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Panina E; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Jahn N; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Herzig J; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Kubanek L; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Schrade A; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Göhring G; Department of Human Genetics, Hannover Medical School, Hannover, Germany., Fiedler W; Hubertus Wald University Cancer Center, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany., Kindler T; Department of Hematology, Medical Oncology, and Pneumology, University Cancer Center Mainz, Mainz, Germany., Schroeder T; Department of Hematology, Oncology, and Clinical Immunology, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany., Mayer KT; Department of Hematology and Oncology, University Hospital Bonn, Bonn, Germany., Lübbert M; Department of Medicine I, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany., Wattad M; Department of Hematology, Oncology and Stem Cell Transplantation, Kliniken Essen Süd, Essen, Germany., Götze KS; III. Department of Medicine, Hematology, and Medical Oncology, Technical University of Munich, Munich, Germany., Horst HA; Department of Internal Medicine II, University Hospital Schleswig Holstein, Campus Kiel, Kiel, Germany., Koller E; III. Department of Medicine, Hematology, and Medical Oncology, Hanuschkrankenhaus Wien, Vienna, Austria., Wulf G; Department of Hematology and Oncology, Georg-August-University Göttingen, Göttingen, Germany., Schleicher J; Department of Hematology and Oncology, Katharinenhospital Stuttgart, Stuttgart, Germany., Bentz M; Department of Internal Medicine III, Municipal Hospital of Karlsruhe, Karlsruhe, Germany., Krauter J; Department of Internal Medicine III, Municipal Hospital of Braunschweig, Braunschweig, Germany., Bullinger L; Department of Hematology, Oncology, and Tumorimmunology, Charité University Medicine Berlin, Campus Virchow Klinikum, Berlin, Germany., Krzykalla J; Division of Biostatistics, German Cancer Research Center, Heidelberg, Germany., Benner A; Division of Biostatistics, German Cancer Research Center, Heidelberg, Germany., Schlenk RF; Nationales Centrum für Tumorerkrankungen Trial Center, National Center of Tumor Diseases, German Cancer Research Center, Heidelberg, Germany.; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany; and., Thol F; Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Heuser M; Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Ganser A; Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Döhner H; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Döhner K; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany.

Publikováno v: Blood [Blood] 2020 Dec 24; Vol. 136 (26), pp. 3041-3050.